KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Change in Cash (2016 - 2025)

Pfizer (PFE) has disclosed Change in Cash for 17 consecutive years, with -$196.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Cash fell 335.56% to -$196.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $91.0 million, a 105.03% increase, with the full-year FY2025 number at $91.0 million, up 105.03% from a year prior.
  • Change in Cash was -$196.0 million for Q4 2025 at Pfizer, up from -$301.0 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $1.8 billion in Q2 2023 to a low of -$2.1 billion in Q1 2024.
  • A 5-year average of $40.3 million and a median of $119.0 million in 2021 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: surged 3626.67% in 2022, then plummeted 1137.93% in 2025.
  • Pfizer's Change in Cash stood at $209.0 million in 2021, then crashed by 409.09% to -$646.0 million in 2022, then skyrocketed by 51.08% to -$316.0 million in 2023, then skyrocketed by 85.76% to -$45.0 million in 2024, then tumbled by 335.56% to -$196.0 million in 2025.
  • Per Business Quant, the three most recent readings for PFE's Change in Cash are -$196.0 million (Q4 2025), -$301.0 million (Q3 2025), and $213.0 million (Q2 2025).